Welcome to our dedicated page for Prophase Labs SEC filings (Ticker: PRPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ProPhase Labs, Inc. (PRPH) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries to help interpret complex documents. ProPhase is a biotech, genomics, and consumer health company, and its filings offer detailed information on diagnostics programs, genomics initiatives, consumer products, financing arrangements, and governance matters.
Investors can review current and periodic reports such as Forms 10-K and 10-Q (when available) for discussions of business operations, risk factors, and financial statements. Form 8-K filings are particularly active for PRPH and capture material events including the 1-for-10 reverse stock split approved and implemented in late 2025, at-the-market equity sales agreements, senior secured convertible notes and warrants described in the S-1 registration statement, and updates on legal matters and lease forbearance arrangements. Our AI tools highlight the key points in these filings, such as the rationale for the reverse split, the structure of financing instruments, and the implications of special meeting votes.
For those analyzing capital structure and dilution, the S-1 registration statement filed in October 2025 details the terms of senior secured convertible notes, associated warrants, and registration rights for resale of common stock. AI summaries can help clarify conversion mechanics, floor price concepts, warrant terms, and potential issuance scenarios, without requiring readers to parse every technical clause.
This page also surfaces proxy materials like the definitive proxy statement for the November 2025 special meeting, where stockholders voted on digital asset charter amendments, digital treasury shares, tokenized issuance authority, and stock split and share authorization proposals. Our AI analysis can outline what each proposal authorizes and how it may affect governance, treasury strategy, and future capital actions.
As new filings are posted to EDGAR, they are updated here in near real time. Users can quickly locate 8-Ks on financial results, legal proceedings, or strategic LOIs, as well as registration statements and other key documents. The combination of official SEC text and AI-generated explanations helps investors, analysts, and researchers understand how ProPhase’s diagnostics, genomics, consumer health businesses, and financing activities are reflected in its regulatory record.
ProPhase Labs has started exploring a potential sale or strategic partnership for BE-Smart™, its clinically validated esophageal cancer risk stratification test. BE-Smart™ is a CLIA-certified, CAP-accredited laboratory-developed test that the company says is ready for commercialization under the current LDT framework.
The company has begun outreach to more than 70 potential acquirers to gauge interest in a transaction. It also reported a positive update on efforts to collect legacy COVID-19 testing receivables through its Crown Medical Collections initiative, noting that over 60% of aggregate claims involve commercial payors that partially reimbursed claims, a category typically linked to higher recovery rates and more favorable settlement dynamics.
ProPhase Labs, Inc. filed a current report to highlight an investor-focused communication event. On February 2, 2026, the company issued a press release inviting investors to a webinar scheduled for February 3, 2026 at 4:15 p.m. Eastern Time.
The webinar was intended to provide insight into ProPhase’s portfolio of high-growth healthcare assets and included a live question-and-answer session with attendees. The press release containing additional details about the event is furnished as Exhibit 1.1 to the report.
ProPhase Labs, Inc. filed a current report to share that it has issued a new press release about its efforts to recover legacy COVID-19 testing receivables. The update focuses on the Company’s Crown Medical Collections initiative, which is working on amounts owed to its laboratory subsidiaries that are currently in Chapter 11 proceedings. The press release, dated January 26, 2026, is attached as an exhibit to the report, providing more detail on the operational progress of this collection effort.
ProPhase Labs, Inc. filed a current report to inform shareholders that its common stock has been approved for trading and uplisted from the Pink Sheets to the OTCID Market. This change was announced in a press release dated January 22, 2026, which is included as an exhibit.
The move from the Pink Sheets to the OTCID Market reflects a change in the trading venue for the company’s common stock under the symbol PRPH.
ProPhase Labs, Inc. entered into a Stock Purchase Agreement with Generating Alpha Ltd., giving the company the right to draw up to
As a commitment fee for establishing this facility, ProPhase issued 549,105 shares of common stock and a prefunded common stock purchase warrant to acquire up to 240,369 shares, with an exercise price of
ProPhase Labs, Inc. is having its common stock removed from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. Nasdaq has certified that it has complied with its own rules to strike this class of securities from listing and registration, and that the issuer has complied with applicable exchange rules and regulatory requirements for voluntary withdrawal. The notification is signed on behalf of Nasdaq by a hearings advisor, confirming the exchange’s belief that it meets all requirements to file Form 25.
ProPhase Labs, Inc. reported on recent volatility in its common stock and explained several technical factors affecting its capital structure. The company highlighted accelerated conversion and resale of its convertible debt, a 1-for-10 reverse stock split effective December 5, 2025, and its transition from the Nasdaq Capital Market to trading on the OTC market effective January 5, 2026, following a Nasdaq delisting that may reduce liquidity and institutional interest.
More than $3,300,000 of convertible debt principal has been converted out of approximately $3,800,000 originally outstanding, reducing debt and increasing stockholders’ equity, but adding a substantial number of shares to the public market. Management stated that most conversion activity is complete, with less than $500,000 principal remaining, and noted that recent conversions were at a floor conversion price of $0.76 per share. The company emphasized that these mechanics have not changed the intrinsic value of its operating subsidiaries and that it remains focused on stabilizing its capital structure, completing near-term financing initiatives, and advancing its core businesses.
ProPhase Labs, Inc. reported that Board member Warren Hirsch resigned from the Board of Directors effective immediately on January 5, 2026. The company states that Mr. Hirsch’s resignation was not due to any disagreement with ProPhase Labs regarding its operations, policies, or practices, indicating an orderly and non-contentious departure. The Board and the company expressed appreciation for his service and contributions during his tenure.
ProPhase Labs, Inc. is implementing a 1-for-10 reverse stock split of its common stock. Stockholders approved the amendment to the Certificate of Incorporation and the Board of Directors authorized it, with a Certificate of Amendment filed in Delaware on December 2, 2025. The reverse split is intended to increase the trading price of the stock to meet continued Nasdaq listing requirements and becomes effective at 8:00 a.m. Eastern Time on December 22, 2025.
At that time, every 10 shares of common stock will automatically be combined into 1 share. No fractional shares will be issued; instead, any fractional amount will be rounded up so each affected holder receives one whole share. The reverse split applies uniformly, does not change the par value or authorized share count, and is not designed to alter relative ownership percentages aside from rounding. Following the effective date, the company expects to have approximately 5,768,951 shares outstanding, with proportionate adjustments to equity awards, warrants and other convertible securities.
ProPhase Labs, Inc. is implementing a 1-for-10 reverse stock split of its common stock to increase the per-share trading price and meet continued Nasdaq listing requirements. The split, previously approved by stockholders on November 24, 2025 and by the board on November 30, 2025, follows a Certificate of Amendment filed in Delaware on December 2, 2025 and becomes effective at 8:00 a.m. Eastern Time on December 22, 2025.
At the effective time, every 10 shares will combine into 1 share, with fractional positions rounded up so affected holders receive a whole share. The company expects to have approximately 5,768,951 shares of common stock issued and outstanding after the reverse split. The action applies uniformly to all stockholders and does not change the par value, authorized share count, or rights of the common stock, and related equity awards, warrants and other convertible securities will be adjusted proportionately while trading continues on Nasdaq under the PRPH symbol.